An inactivated vaccine for the control of bluetongue virus serotype 16 infection in sheep in Italy

Veterinary Microbiology

Volumn 124, Issue 1-2, 2007, Pages 140-146

  Savini, G ^a   Ronchi, G F ^a   Leone, A ^a   Ciarelli, A ^a   Migliaccio, P ^a   Franchi, P ^a   Mercante, M T ^a   Pini, A ^a  

^a ISTITUTO ZOOPROFILATTICO SPERIMENTALE DELL ABRUZZO E DEL MOLISE G CAPORALE   (Italy)

Author keywords

Bluetongue virus serotype 16; Inactivated vaccine; Sheep; Virus isolation; Virus neutralisation

Indexed keywords

INACTIVATED VIRUS VACCINE; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; BLUETONGUE ORBIVIRUS; CONTROLLED STUDY; GUINEA PIG; HYPERTHERMIA; INJECTION SITE INFLAMMATION; INJECTION SITE REACTION; ITALY; MOUSE; NONHUMAN; RNA VIRUS INFECTION; SEROTYPE; SHEEP; SHEEP DISEASE; VIREMIA; VIRUS TYPING;

ANIMALS; ANTIBODIES, VIRAL; BLUETONGUE; BLUETONGUE VIRUS; BODY TEMPERATURE; GUINEA PIGS; ITALY; MICE; NEUTRALIZATION TESTS; RANDOM ALLOCATION; SEROTYPING; SHEEP; TIME FACTORS; VACCINES, INACTIVATED; VIRAL VACCINES; VIREMIA;

ANIMALIA; BLUETONGUE VIRUS; OVIS ARIES;

EID: 34547684493     PISSN: 03781135     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vetmic.2007.04.017     Document Type: Article

References (35)

1. Altman A., and Dixon F.J. Immunomodifiers in vaccines. Adv. Vet. Sci. Comp. Med. 33 (1989) 301-343
2. Anderson G.A., Stott J.L., Gershwin L.J., and Osburn B.I. Subclinical and clinical disease in cattle: clinical, pathological and pathogenic considerations. In: Barber T.C., Jochim M.S., and Osburn B.I. (Eds). Bluetongue and Related Orbiviruses. Progress in Clinical and Biological Research vol. 178 (1985), Alan R. Liss Inc., New York 53-65
3. Barnett P.V., Pullen L., Williams L., and Doel T.R. International bank for foot-and-mouth disease vaccine: assessment of Montanide ISA 25 and 206, two commercially available oil adjuvants. Vaccine 14 (1996) 1187-1198
4. Calistri P., Giovannini A., Conte A., Nannini D., Santucci U., Patta C., Rolesu S., and Caporale V. In: MacLachlan N.J., and Pearson J.E. (Eds). Bluetongue in Italy. Part I vol. 40 (2004), Bluetongue, Veterinaria Italiana 243-251
5. Cook D.R., Hill H.T., and Kinker D.R. Efficacy of a killed gpx deleted pseudorabies virus vaccine. Can. J. Vet. Res. 54 (1990) 438-445
6. European Commission, 1991. Commission Directive 91/412/EEC of July 23, 1991 Laying Down the Principles and Guidelines of Good Manufacturing Practice for Veterinary Medicinal Products. Off. J. L228, 17/08/1991, pp. 70-73.
7. European Commission, 2001. Commission Decision CEE 2001/141/EC of February 20, 2001 for the implementation of a bluetongue vaccination programme in certain parts of the protection zone in Italy and the purchase by the Community of vaccine for this purpose (notified under document number C (2001) 424). Off. J., L050, 21/02/2001, pp. 23-24.
8. European Council, 1981. Council Directive 81/852/EEC on the Approximation of the Laws of the Member States relating to Analytical, Pharmaco-Toxicological and Clinical Standards and Protocols in respect of the Testing of Veterinary Medicinal products. Off. J., L 317, 6/11/1981, pp. 53-98.
9. European Pharmacopoeia. Addendum no. 0016 (2001), Council of Europe, Strasbourg
10. Italian Ministry of Health, 2005. Nota del 19 gennaio 2005, no. 1720. Bluetongue-provvedimenti ed impiego del vaccino sierotipo 16 nella IV campagna di vaccinazione 2004-2005.
11. Lelli R., Langella V., Portanti O., Luciani M., Di Emidio B., and Conte A.M. Production of a competitive ELISA kit for the serological diagnosis of bluetongue disease. Veterinaria Italiana 47 (2003) 5-13
12. Lobato Z.I., Coupar B.E., Gray C.P., Lunt R., and Andrew M.E. Antibody responses and protective immunity to recombinant vaccinia expressed-expressed bluetongue virus antigens. Vet. Immunol. Immunopathol. 59 (1997) 293-309
13. Martinez D., Perez P.M., Sheikboudou C., Debus A., and Bensaid A. Comparative efficacy of Freunds and Montanide ISA 50 adjuvants for the immunization of goats against heart water with inactivated Cowdria ruminantium. Vet. Parasitol. 67 (1996) 175-184
14. Mellor P.S. Culicoides as potential orbivirus vectors in Europe. In: Walton T.E., and Osburn B.I. (Eds). Bluetongue, African Horse Sickness and Related Orbiviruses (1992), CRC Press Inc., Boca Raton, Florida 278-283
15. Mellor P.S., and Wittmann E.J. Bluetongue virus in the Mediterranean Basin 1998-2001. Vet. J. 164 (2002) 20-37
16. Monaco F., Cammà C., Serini S., and Savini G. Differentiation between field and vaccine strain of bluetongue virus serotype 16. Vet. Microbiol. 116 (2006) 45-52
17. Murray P.K., and Eaton B.T. Vaccine for bluetongue. Aust. Vet. J. 73 (1996) 207-210
18. OIE World Organisation for Animal Health. Bluetongue in The Netherlands. Dis. Inform. 19 (2006) 612-613
19. OIE World Organisation for Animal Health. Bluetongue in Belgium. Dis. Inform. 19 (2006) 616-617
20. OIE World Organisation for Animal Health. Bluetongue in Germany. Dis. Inform. 19 (2006) 618
21. OIE World Organisation for Animal Health. Bluetongue in France. Dis. Inform. 19 (2006) 636-637
22. OIE World Organisation for Animal Health. Bluetongue in Bulgaria. Dis. Inform. 19 (2006) 736
23. OIE World Organisation for Animal Health. Bluetongue in Italy. Dis. Inform. 19 (2006) 775-776
24. OIE World Organisation for Animal Health. Bluetongue in Israel. Dis. Inform. 19 (2006) 842
25. OIE World Organisation for Animal Health. Bluetongue in Luxembourg. Dis. Inform. 19 (2006) 852
26. Parker J., Hernimann K.A.J., and Gibbs E.P.J. An experimental inactivated vaccine against Bluetongue. Vet. Rec. 96 (1975) 284-287
27. Roy P., Urakawa T., Van Dijk A.A., and Erasmus B.J. Recombinant virus vaccine for bluetongue disease in sheep. J. Virol. 64 (1990) 1998-2003
28. Roy P., French T., and Erasmus B.J. Protective efficacy of virus-like particles for bluetongue disease. Vaccine 10 (1992) 28-32
29. Roy P., Bishop D.H., LeBlois H., and Erasmus B.J. Long-lasting protection of sheep against bluetongue challenge after vaccination with virus-like particles: evidence for homologous and partial heterologous protection. Vaccine 12 (1994) 805-811
30. Roy P. Genetically engineered structure-based vaccine for bluetongue disease. Veterinaria Italiana 40 (2004) 594-600
31. Savini G., Monaco F., Migliaccio P., Casaccia C., Salucci S., and Di Ventura M. In: MacLachlan N.J., and Pearson J.E. (Eds). Virological and Serological Responses in Sheep following Field Vaccination with Bivalent Live-modified Vaccine against Bluetongue Virus Serotypes 2 and 9 vol. 40 (2004), Bluetongue, Veterinaria Italiana 479-483
32. Savini G., Goffredo M., Monaco F., Di Gennaro A., Cafiero M.A., Baldi L., De Santis P., Meiswinkel R., and Caporale V. Bluetongue virus isolations from midges belonging to the Obsoletus complex (Culicoides Diptera: Ceratopogonidae) in Italy. Vet. Rec. 157 (2005) 133-139
33. Savini, G., Nicolussi, P., Pilo, G., Colorito, P., Fresi, S., Teodori, L., Leone, A., Bonfini, B., Patta, C., 2006. Studio sulla sicurezza ed efficacia di un vaccino ricombinante nei confronti del virus della Bluetongue sierotipo 2. Veterinaria Italiana.
34. Siegel S., and Castellan N.J. Non-parametric Statistics for the Behavioral Sciences. 2nd ed. (1988), McGraw-Hill Book Co., New York, USA
35. Verwoerd D.W., and Erasmus B.J. Bluetongue. In: Coetzer J.A.W., Thomson G.R., and Tutsin R.C. (Eds). Infectious Diseases of Livestock with Special Reference to South Africa (1994), Oxford University Press 443-459